12545 El Camino Real
About SignalRX PharmaceuticalsSignalRx is a clinical stage company incorporated in Delaware in 2012 and based in San Diego, California. The company is focused on developing effective anticancer treatments based on blocking the most important and critical cell signaling pathways that cancer cells use to proliferate, migrate, metastasize, and recruit a blood supply. One of our most advanced programs is centered on the PI3 kinase pathway where our lead compounds go beyond the traditional kinase-inhibition mode of action by additionally inducing oxidative stress and inhibiting reflux-pump resistance mechanisms in cancer cells.
Founders: Joseph R. Garlich, Guillermo A. Morales, and Donald L. Durden
CSO: Joseph R. Garlich
Founder and CBO: Guillermo A. Morales
Please click here for clinical trial information.
9 articles with SignalRX Pharmaceuticals
SignalRx Pharmaceuticals Inc. announced the in silico design and discovery of SRX3254, a highly potent and selective inhibitor of the binding domain 1 (BD1) of the bromodomain protein BRD4 (BRD4-BD1).
SignalRx announces its proprietary small molecule dual inhibitor of PI3K and BRD4, SF2523, demonstrates "Shock and Kill" effects on latent HIV virus as a promising approach to curing AIDS
SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics to inhibit key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the publication in the Journal of Biological Chemistry studies demonstrating its dual PI3K/BRD4 inhibitor SF2523 suppresses HIV-1 replication and eliminates the latent infectious state.
SignalRx to Present on its First-In-Class Triple CDK4-6/PI3K/BRD4 Inhibitor SRX3177 for Treating Cancer at the 13th Annual Drug Discovery Chemistry 2018 Meeting
SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the presentation of its novel triple CDK4-6/PI3K/BRD4 inhibitor program and first-in-class triple inhibitor SRX3177.
SignalRx Announces in Silico Design and Discovery of the First-in-Class HDAC6-BRD-PI3K Epigenetic Kinase Inhibitor SRX3225
SignalRx's proprietary CRIMP technology platform led to the in silico design and identification of SRX3225 within its triple inhibitor program.
SignalRX Pharmaceuticals Presents In Silico Design Of Dual PI3K/BRD4 Inhibitors For Combinatorial Activation Of Anti-Tumor Immunity In Treating Cancer
SignalRX Pharmaceuticals Awarded $2M Phase II STTR Grant From NCI For The Development Of Epigenetic-Kinase Inhibitors As Anticancer Agents
SignalRX Pharmaceuticals Discloses Its Novel Immuno-Oncology Program Approach At The 12th Annual Drug Discovery Chemistry 2017 Meeting
SignalRX Pharmaceuticals To Present At The AACR Annual Meeting On Its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 For Treating Cancer
SignalRX Pharmaceuticals Announces Breakthrough Results On Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm In PNAS Publication